title: [Long-term selective beta 1-blockade therapy for a patient with anthracycline-induced cardiomyopathy].
abstract: A 44 year-old woman with acute myeloid leukemia (AML, FAB, M4E) developed heart failure during treatment with anthracyclines for AML. She had not experienced heart disease and her left ventricular ejection fraction (LVEF) was 59% at the end of a successful remission induction therapy. Because her LVEF decreased to 33% after early consolidation therapy, the chemotherapy for AML was discontinued. The cumulative dose of daunorubicin, aclarubicin and mitoxantrone was 486 mg/m2, 135 mg/m2 and 55 mg/m2, respectively. In October 1990, four months after the end of the chemotherapy, heart failure (class III, NYHA) developed and did not improve by treatment consisting of dobutamin, digoxin and diuretics. Anthracycline cardiomyopathy was histologically confirmed by endomyocardial biopsy. Then we administered selective beta 1-antagonist, metoprolol (Seloken), with an initial dose of 5 mg/day which was doubled 3 times every 4 or 8 weeks to 40 mg/day, according to the treatment schedule of dilated cardiomyopathy. She recuperated satisfactorily (Class I, NYHA), and was discharged on February '91. Her LVEF gradually improved and it has been maintained at above 50% on an outpatient basis. The patient has been in complete hematological remission during this period. It seems that low dose selective beta 1-antagonist therapy has a potential to improve myocardial function in some patients with anthracycline cardiomyopathy.
authors.affiliation: Department of Medicine, Fujita Health University School of Medicine, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Okamoto
authors.forename: H
authors.initials: H
authors.lastname: Miyazaki
authors.forename: M
authors.initials: M
authors.lastname: Tsuzuki
authors.forename: T
authors.initials: T
authors.lastname: Ino
authors.forename: K
authors.initials: K
authors.lastname: Ezaki
authors.forename: M
authors.initials: M
authors.lastname: Hirano
mesh_terms: D015250:Aclarubicin / Q000009:adverse effects; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage*; D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D002312:Cardiomyopathy, Hypertrophic / Q000139:chemically induced / Q000188:drug therapy*; D002908:Chronic Disease; D003630:Daunorubicin / Q000009:adverse effects; D004334:Drug Administration Schedule; D005260:Female; D006333:Heart Failure / Q000139:chemically induced / Q000188:drug therapy*; D006801:Humans; D015479:Leukemia, Myelomonocytic, Acute / Q000188:drug therapy; D008790:Metoprolol / Q000008:administration & dosage*; D008942:Mitoxantrone / Q000009:adverse effects
chemical_list: D000319:Adrenergic beta-Antagonists; D000903:Antibiotics, Antineoplastic; D015250:Aclarubicin; D008942:Mitoxantrone; D008790:Metoprolol; D003630:Daunorubicin